Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27495410 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19L3MBTL1NPY5R | |
| SCHEMBL19366192 | 0.81 | RORC (0.60) | L3MBTL1EPHX2SMN1; SMN2GAARORC | |
| SCHEMBL2123696 | 0.81 | EPHX1 (0.46) | EPHX2SMN1; SMN2RORCMEN1LMNA | |
| SCHEMBL4403329 | 0.80 | EPHX1 (0.63) | CYP1A2CYP2C9CYP2C19L3MBTL1EPHX2 | |
| SCHEMBL16621003 | 0.80 | SMN1; SMN2 (0.60) | CYP1A2CYP2C9CYP2C19L3MBTL1EPHX2 | |
| SCHEMBL22166698 | 0.79 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19L3MBTL1NPY5R | |
| SCHEMBL10615069 | 0.79 | MEN1 (0.62) | GAARORCMEN1LMNAKMT2A | |
| SCHEMBL9633496 | 0.78 | SMN1; SMN2 (0.47) | EPHX2SMN1; SMN2RORCLMNAMAPT | |
| SCHEMBL11097805 | 0.77 | KIF11 (0.54) | CYP1A2CYP2C9CYP2C19L3MBTL1NPY5R | |
| SCHEMBL13602467 | 0.77 | L3MBTL1 (0.54) | CYP1A2CYP2C9CYP2C19L3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172473-A1 | DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE | JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN (DE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172473-A1 | DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE | NR1H4, NR1H3, NR1H2 | CYP1A2 274/4885CYP2C9 712/4885CYP2C19 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.